laptop for fluidics control, data analysis and storage. For commercial use with a more standardized range of applications, a much simpler user interface could be implemented. The current NRL system is robust, small, and automated, but it is clearly a laboratory prototype assembled by scientists-not by manufacturing experts with a view to assembly-line production.
It is the purpose of this review to provide a snapshot of the technology as it exists today with a glimpse into the future provided by our corporate partners.
The NRL Array Biosensor
The NRL Array Biosensor was developed to analyze multiple samples for multiple analytes and was designed to be portable and easy to use for untrained personnel (Fig. 1) . [12] [13] [14] [15] The sensor system consists of a 50 W power supply (Sunpower), a cooled CCD camera (Retiga 1300, Q-Imaging), peristaltic pumps (P625/66.143, Instec) and valves (Lee Company), and machined fluidics chambers. All components are mounted within a portable carrying case (Zero Enclosures) and the entire system weighs approximately 15 pounds. The peristaltic pumps and valves are controlled using a serial interface from a laptop computer via an interface board (ADR-2000, Ontrak Control Systems) that converts the RS-232 signals into the required digital and analog control voltages. A control program written with LabWindows (National Instruments) provides a simple user interface to control the timing and flow of assay reagents. Also contained within the carrying case is a 635 nm diode laser (LAS-635-15, Lasermax) equipped with a line generator to spread the laser beam into a fan pattern. The expanded laser beam is launched into the edge of the microscope slide waveguide, thus providing even fluorescence excitation. The cooled CCD camera images the fluorescent array on the microscope slide through a 700 ± 35 nm bandpass filter (P70-700-S, Corion) and a 665 nm longpass filter (RG665, Schott Glass) using a 17 mm C-mount lens (Schneider Optics). The image is acquired through a Firewire (IEEE 1394) connection, eliminating the need for a bulky frame grabber board and allows all aspects of sensor function to be controlled by a laptop.
The Array Biosensor uses two removable six-chamber reservoir modules (Fig. 1) , each fitted with a rubber septum on the bottom. Blunt needles mounted on the module platform penetrate pre-punched holes in the rubber septa upon insertion of the modules into the system, connecting the reservoirs to the rest of the fluidics system.
A vertical slide mount equipped with a spring-loaded plate presses the microscope slide against a six-channel gasket molded in poly(dimethylsiloxane) (PDMS, NuSil Silicone Technology), forming the six-assay flow channels. Each of the six channels is connected to a pump that draws flow from one end of the channel. The opposite end of each channel (inlet) is connected to a 2-way valve; these valves switch between the two sources of fluid (sample reservoirs, tracer reservoirs) flowing through the channels. The fluidics system was designed with the slide and flow channels in an upright position, rather than horizontally oriented as found in many other imaging systems; the purpose of this configuration was to keep the fluidics components separate from the optics and electronics so that any potential fluid leaks would not damage the optical or electronic components.
A LabWindows-based image analysis program has been written to locate the array elements using a virtual grid after the array image is loaded. The software then automatically extracts the average pixel intensities from the assay spots and from the regions between the spots; regions between the assay spots are considered background and are used in determining the net fluorescent signal.
The data are exported to an Excel spreadsheet where three variables are used to determine whether a sample is considered positive for each array spot: 1) a simple intensity determination calculates the net signal intensity of each array spot (intensity above background) and determines whether it is above a pre-set threshold value; 2) the signal-tobackground noise ratio (signal intensity divided by the standard deviation of the background region) is also compared to a separate pre-set threshold value; and 3) the intensity of the array element in the sample lane must be equal or greater in value than the corresponding element in the negative control lanes. After equal weights are given to each of these variables, the overall score is calculated and compared to another user-defined threshold score for the final determination of positive or negative detection.
Antibody-based Detection
Because of their selectivity and sensitivity, immunoassays have been the first choice for developing rapid identification methods using the fluorescence-based NRL Array Biosensor. 14, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Table  1 provides detailed information on the assays including limits of detection (LOD). The LOD was calculated as the lowest concentration tested which gave a signal 3 standard deviations above the blank. The biosensor takes advantage of the planar waveguide coupled with PDMS flow cells to allow simultaneous detection and quantification of multiple target analytes (up to nine currently demonstrated) in multiple samples. 33 Due to public health risks, much of the recent work in assay development has concentrated on the rapid detection of foodborne contaminants. The NRL Array Biosensor has been used for the measurement of a number of protein toxins, such as staphylococcal enterotoxin B (SEB) 22, 23 and botulinum toxoid A, 22 and bacteria, including Campylobacter spp., 29 Shigella spp., 29 Escherichia coli 32 and Salmonella enterica serovar Typhimurium, 28 in a variety of spiked food matrices. Analyte detection is rapid, with immunoassays taking 10 -45 min, is simple to perform and requires minimal sample processing. While sandwich immunoassays work extremely well for the larger protein and bacterial foodborne contaminants, small analytes, such as mycotoxins, are not large enough to contain separate recognition sites for both the capture and tracer antibodies. For this reason, competitive immunoassays have been successfully developed for detection of the mycotoxins ochratoxin A, 20, 35 aflatoxin B1, 21 and deoxynivalenol 19, 35 in spiked and naturally contaminated foods. The feasibility of running both sandwich and competitive formats on the same waveguide surface has recently been demonstrated, allowing the user to measure large and small molecular weight target analytes simultaneously, as well as multiplexing the competitive immunoassays, see Fig. 2 . 34, 35 In addition, the NRL Array Biosensor is capable of performing real-time binding analyses and has been used to determine kinetic and affinity constants for both specific, 36 semi-selective, 37 and non-specific 38 binding interactions. The NRL Array Biosensor has recently been used in the development of multiplexed assays for screening of human sera for antibodies directed against bacterial and viral antigens, including SEB, tetanus toxin, diphtheria toxin and hepatitis B. 39 Such a biosensor could potentially be used in a clinical setting to monitor individuals for exposure to various pathogens or to study the efficacy of vaccination.
Detection Based on Non-antibody Molecules
While antibodies offer high specificity for many of the immunoassays developed using the NRL Array Biosensor, we are also investigating the use of alternative capture molecules for the detection of bacterial toxins and bacterial targets. For example, the cellular receptor ganglioside GM1 was used to capture cholera toxin, through ligand-receptor interactions. 40 Mono-and oligosaccharides, considered the "working end" of ganglioside receptors, have also been used to detect toxins using the NRL Array Biosensor. Immobilized monosaccharides Nacetylneuraminic acid (Neu5Ac) and N-acetylgalactosamine (GalNAc) were screened for their ability to capture Cy5-labeled, Escherichia coli O157:H7, Salmonella typhimurium, Listeria monocytogenes, SEB, and cholera and tetanus toxins. 41 Fluorescent signals obtained from the Array Biosensor demonstrated that only the cholera and tetanus toxins interacted with the immobilized sugars, while none of the tested bacterial targets bound to these monosaccharides; these results were not surprising, as these bacteria have specificity for carbohydrate 7 ANALYTICAL SCIENCES JANUARY 2007, VOL. 23 moieties different from those tested. Furthermore, SEB, whose receptor is not sugar-based, did not bind to either of these carbohydrates nor to any of the other carbohydrates tested. Antimicrobial peptides are another class of non-antibody recognition molecules used for detection of pathogens and toxins with the NRL Array Biosensor. Antimicrobial peptides are naturally occurring molecules that serve as part of the innate immune system of many organisms and work by disrupting cell membranes. Kulagina and coworkers immobilized magainin I and other antimicrobial peptides onto glass slides and were able to measure Cy5-labeled Escherichia coli O157:H7 and Salmonella typhimurium, 42, 43 with limits of detection in the same range as analogous antibody-based assays. Other microbial species (including inactivated preparations of Brucella melitensis, Coxiella burnetti, and two enveloped viruses) 44 have also been detected on the NRL Array Biosensor using antimicrobial peptide-based assays. A significant enhancement in stability was demonstrated with antimicrobial peptides and clear differences in binding patterns of the bacterial species were demonstrated. 43, 44 Both carbohydrates and antimicrobial peptides bind semiselectively and are capable of interacting with multiple targets. A multi-peptide or multi-carbohydrate array could therefore complement the more selective antibody capture immunoassays in a multi-capture array format. Such a multiplexed peptideand/or carbohydrate-based detection system could measure families of bacterial targets or toxins, rather than requiring one antibody for each target species. More importantly, such a system could potentially pick up unknown targets not preselected for measurement by the more specific antibody-based systems. As these semi-selective capture molecules have overlapping specificities, the patterns of binding could potentially be used for specific identification.
The capture molecules have been deposited on the planar waveguides (avidin-coated microscope slides) using two principle approaches. The first and simplest approach involves use of a poly(dimethylsiloxane) "patterning" template with parallel channels running perpendicular to the long axis of the slide. After the template is placed in contact with the avidincoated slide, biotinylated capture molecules are introduced into the channels to form stripes of capture molecules across the slide. When the patterned slide is inserted into the array biosensor, sample and the fluorescent reagent are introduced in channels parallel to the long axis of the slide so that the sample is exposed to all stripes of the immobilized capture molecules. Positive reactions show up as small squares the width of the channels used; typically 1 mm 2 spots are produced with up to 15 spots per channel. The second approach is to deposit round spots using a contact or noncontact printer of the type used to make DNA arrays; these spots are printed into locations corresponding to the length of the sample channels. We have demonstrated assays with thirty-two 200-micron spots per channel, 45 but twice as many spots could easily fit in each channel. The CCD camera is capable of measuring smaller spots; decrease in spot size would allow even more spots per channel.
Blind Trials
As a demonstration of on-site detection capability, the NRL Array Biosensor has been involved in several blind trials -one using a non-automated prototype 31 and two using the fully automated, self-contained units. One of the latter two trials was held at Dugway Proving Grounds and involved the detection of inactivated biothreat agents in 316 samples, 46 while the second trial was an FDA laboratory trial for the detection of foodborne contaminants in 216 spiked water, apple juice, and milk samples. In both of these latter trials, analyses of 4 samples plus 2 controls were completed in less than 45 min, with automated handling of all fluidics components after initial loading of the samples and tracer antibodies. During the Dugway trial, a Naval reservist trained in only 4 h performed analyses of approximately 150 samples, demonstrating the instrument's ease of use. The blind trial of spiked foods demonstrated the capability of the fully automated system for potential field use by inspectors with answers available onsite; spiked samples were simply brought to neutral pH before analysis and answers were available 45 min later. The system was able to detect SEB below 1 ng/ml in spiked water and apple juice sample. Some loss in sensitivity was observed in the presence of milk, considered by food analysis experts to be a highly challenging matrix; however, SEB was still detectable at 1 ng/ml in milk samples. Similarly, S. typhimurium was detectable at lower levels in water and apple juice (5 × 10 3 to 5 × 10 4 cfu/ml), but required somewhat higher levels when spiked into milk. The FDA trials were, to our knowledge, the first ever blind trial of an automated biosensor used for detection of multiple foodborne contaminants in blind samples of spiked foods.
Commercial Versions of the Array Biosensor
Three companies, Hanson Technologies, Constellation Technology Corp. and Precision Photonics Corp., have licensed the technology relevant for operating the NRL Array Biosensor and are producing the biosensor to sell for a host of different applications.
6·1
The Hanson Technologies' Leopard: It is fast, agile, and has spots Hanson Technologies (www.hansontechnologies.com) has modified the NRL Array Biosensor laboratory prototype (Fig.  1) into an instrument ready for commercial production (Fig. 3) . Several improvements have been made to the design of the mechanical and electrical systems to improve performance, maintenance and durability. In addition, an enclosed case was designed to keep the mechanical and electrical components in a secure, light-tight environment. The case allows easy access to the region where slides are inserted for both running experiments and maintenance. A proprietary software control interface is now provided for ease of operation and test result interpretation. The software is combined with a much improved series of fluidic sections for consistent and repeated operation of the instrument. The result is a rugged, easy to use, and reliable biosensor. It can be used both by skilled and highly educated laboratory staff, and by less skilled technicians in a commercial environment.
6·2 The Constellation Technologies Array Biosensor (CT-ABS)
Constellation Technologies (www.contech.com) has developed a completely automated and self-contained (no external computer) instrument, called the CT-ABS (Fig. 4) , which allows a user in the field to manually execute the immunoassay process or to integrate the CT-ABS unit into an automated biodetection system. The CT-ABS consumables are contained in mass producible cartridges. One cartridge contains the waveguide patterned with capture antibody and the flow chamber. A separated cartridge contains detection antibody reservoirs. These cartridges allow a user in the field to easily replace consumables.
After sample introduction, the unit automatically executes all the CT-ABS immunoassay steps, as well as analyzes the resulting image and provides the user with a positive or negative evaluation.
Constellation has demonstrated the CT-ABS integrated with a number of sample collection devices including an aerosol-to-hydrosol air collector and a filter/concentrator for biological agent detection in water systems. Over a dozen assays, which provide results in 10 -15 min, have been developed for the CT-ABS unit.
Manufacturing of the CT-ABS and cartridges has progressed significantly. Constellation now uses an automated non-contact dispensing machine to mass produce patterned waveguides. The design of the CT-ABS unit has been optimized for cost, reliability, and manufacturability.
6·3 Precision Photonics Corporation-a clinical focus
Precision Photonics (www.precisionphotonics.com) is adapting the NRL Array Biosensor for clinical detection of disease markers, with an emphasis on point-of-care diagnostics in resource limited settings, ranging from clinics in developing countries to the frontlines of a bioterrorist attack. To date the technology has been used for detection of both proteins and antibodies. When adapted for detection of antibodies, the platform provides a useful test for HIV and its common coinfections, a key set of tests to manage clinical treatment. A series of images (Fig. 5) shows data from 6 patients with known disease status: 1 normal patient, 5 HIV patients, and 1 HIV patient who is also positive for the hepatitis C virus (HCV).
The technology has been separated into both a reader and a fluidics cartridge that will be self-contained due to the infectious nature of the samples. Analysis is performed on a laptop. The imaging system fits into a box of approximate dimensions 5 × 15 × 20 cm 3 , with no moving parts. Ultimately, the analysis of the image and display of the results will be automated and self-contained in a compact reader the size of a cell phone. Prototypes of this modified format have been built and are undergoing trials.
Conclusions
The NRL Array Biosensor is a small, portable, automated system that can analyze six samples simultaneously for multiple targets. It can perform both sandwich and competitive assays, detecting both high and low molecular weight targets, in complex sample matrices with minimal if any sample preparation.
The laboratory prototype has demonstrated sensitivity proportional to the affinity of the recognition 9 ANALYTICAL SCIENCES JANUARY 2007, VOL. 23 5 Results from a set of six tests from 6 patient sera using Precision Photonics instrument. The first patient has negative serology, while patients 2 -6 are positive for HIV, and patient 5 is positive for HCV. Each test strip shows six potential spots with reactivity. As labeled, the first two are positive controls, the third is a negative control, and the last three test for reactivity to the viral antigens. molecules used in a wide variety of applications and performed well in blind trials.
The technology is amenable to commercialization for a variety of purposes: the three systems reaching the market now are highlighted above.
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